Kazia Therapeutics Ltd
(NAS:KZIA)
$
5.6601
-0.12 (-2.05%)
Market Cap: 18.85 Mil
Enterprise Value: 16.70 Mil
PE Ratio: 0
PB Ratio: 4.23
GF Score: 39/100 Kazia Therapeutics Ltd at Edison Open House Global Healthcare Conference (Virtual) Transcript
Jan 26, 2022 / 08:00AM GMT
Release Date Price:
$62.5
(-5.45%)
Vivienne Parry
BBC Television - Media
Welcome to Edison Open House Global Healthcare 2022. In this session, we're highlighting the work of Kazia, an Australian oncology biotech focused on solid tumors. To tell me more is CEO, James Garner. Hello, James.
James Garner
Kazia Therapeutics Ltd. - CEO & Executive Director
Hello, Vivienne. Great to be with you again.
Questions & Answers
Vivienne Parry
BBC Television - Media
So first of all, tell me a bit more about the business model of Kazia, which is an unusual one.
James Garner
Kazia Therapeutics Ltd. - CEO & Executive Director
Kazia doesn't invent drugs. We look for drugs that really excite us, but which exist in other companies and which aren't strategic for those companies, they don't fit with the business of the company they're currently in. We look to bring them into Kazia, we take them through clinical trials and we bring them forward to patients.
And the two drugs in our pipeline
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot